Receiving a non-compliance letter from Nasdaq is a significant regulatory issue that directly impacts Iterum Therapeutics. This news could lead to negative investor sentiment in the short term, as it puts the company's listing status at risk. The direct mention of the company and the nature of the compliance issue make this highly relevant and important for investors, leading to a likely decrease in stock price.